From the New England Journal of Medicine. "Currently, after a drug is approved for marketing, we rely on a voluntary reporting system based on the assumption that a drug is safe... It is remarkable that at a time when the technology for collecting and analyzing large amounts of data is readily available, an independent, comprehensive, and systematic program of post-marketing drug surveillance does not exist."

Argues that more emphasis should be given to personal freedom over public health, using the example of alcohol.

This site, in data graphic form, shows U.S. live expectancy trends and health care spending compared to other nations, raising challenging questions today and looking forward.

International human-rights standards can help point a useful direction while we prepare ourseleves to face a new public-health challenge that has come to the fore in the fight against AIDS.

Paper on the managerial takeover of clinical practice, and how the process of medical science is distorted by politics and dubious trendy theories.

Facts sheets explaining attempts to legitimize negligent or incompetent conduct by health care providers.

Legal Information on medical malpractice lawsuits.

An examination of asbestos, its effects on the human body, the state of mesothelioma treatments, and pending legislation on asbestos issues.

Articles explore the Medicare bill and its drug plan, the imported drug controversy, stem cell research, and the Administration's policy for the uninsured.